Medication info
Innozen Abeltan Plus Tablet 300/12.5 mg

Innozen Abeltan Plus Tablet 300/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Irbesartan›300mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
HK Inno.N Co., Ltd.
Appearance
Pink, biconvex, oval film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201005771 · Notified 2010.09.30 · Insurance code 640005860

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
This medicine is administered once daily, regardless of meals. It is recommended that the appropriate dose of each ingredient (irbesartan and hydrochlorothiazide) be determined. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - Administer one tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone. - Administer one tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg. - Administer one tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medicine may be administered in combination with other antihypertensive agents. 2. When considering this medicine as initial therapy for patients with moderate or severe hypertension (stage 2), treatment should be individualized, taking into account baseline blood pressure, the target blood pressure, and the expected increase in the likelihood of reaching the treatment target compared with monotherapy. Treatment is generally initiated with one tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Use of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended in patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred for this patient population. No dose adjustment is necessary in patients with renal impairment whose creatinine clearance is 30 mL/min or higher. ○ Patients with volume depletion If sodium and/or fluid depletion is present, correct the imbalance before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Elderly patients No dose adjustment is necessary for elderly patients.
Child dose
○ Pediatric patients Children and adolescents under 18 years of age: The safety and efficacy of this medicine have not been established.

Ingredients

Manufacturer
HK Inno.N Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
  • moderate hypertension
  • severe hypertension
View approved original text

This medication is used for patients with essential hypertension. It is administered to those who have insufficient blood pressure control with monotherapy and is also used for initial treatment in moderate or severe hypertensive patients requiring combination therapy. This helps effectively control blood pressure and reduce cardiovascular risks.

How to take

Adult dose

This medicine is administered once daily, regardless of meals. It is recommended that the appropriate dose of each ingredient (irbesartan and hydrochlorothiazide) be determined. ○ Adults 1. Patients whose blood pressure is not adequately controlled with monotherapy - Administer one tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 150 mg or hydrochlorothiazide alone. - Administer one tablet of irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg. - Administer one tablet of irbesartan 300 mg/hydrochlorothiazide 25 mg once daily to patients whose blood pressure is not adequately controlled with irbesartan 300 mg/hydrochlorothiazide 12.5 mg. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medicine may be administered in combination with other antihypertensive agents. 2. When considering this medicine as initial therapy for patients with moderate or severe hypertension (stage 2), treatment should be individualized, taking into account baseline blood pressure, the target blood pressure, and the expected increase in the likelihood of reaching the treatment target compared with monotherapy. Treatment is generally initiated with one tablet of irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily; if blood pressure control is needed, the dose may be increased after 1 ~ 2 weeks to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg. Use of this medicine as initial therapy is not recommended in patients with intravascular volume depletion. ○ Patients with renal impairment Because of the hydrochlorothiazide component, this medicine is not recommended in patients with severe renal impairment (creatinine clearance〈 30 mL/min). Loop diuretics are preferred for this patient population. No dose adjustment is necessary in patients with renal impairment whose creatinine clearance is 30 mL/min or higher. ○ Patients with volume depletion If sodium and/or fluid depletion is present, correct the imbalance before administering this medicine. ○ Patients with hepatic impairment This medicine should not be used in patients with severe hepatic impairment. Thiazide drugs should be used with caution in patients with hepatic impairment. No dose adjustment is necessary in patients with mild ~ moderate hepatic impairment. ○ Elderly patients No dose adjustment is necessary for elderly patients.

Child dose

○ Pediatric patients Children and adolescents under 18 years of age: The safety and efficacy of this medicine have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn, especially during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant, potentially pregnant, or nursing should not take this medication. Additionally, patients with a known allergy to this drug or its components, severe renal impairment, anuria, or certain liver diseases should avoid using this medication. Caution is advised in patients with specific conditions such as hypotension, kidney issues, liver disorders, heart valve disease, or angle-closure glaucoma. The hydrochlorothiazide component may increase the risk of skin cancer due to sensitivity to sunlight, so exposure to ultraviolet light should be limited, and skin changes should be closely monitored during use. Various side effects such as dizziness, fatigue, nausea, and abnormal urination may occur; if symptoms are severe or persistent, consult a physician. Hypotensive symptoms may arise during hypertension treatment, so it is important to prevent and manage dehydration or sodium deficiency. Regularly check kidney function and electrolyte levels via blood tests, particularly potassium levels, as they can pose health risks if too high or too low. Be sure to inform a doctor or pharmacist of any other medications being taken as there may be interactions. Diabetic patients may be affected by blood sugar control, so blood sugar levels and treatment plans should be regularly monitored. This medication is not recommended for children or adolescents as safety and efficacy have not been established. Older patients may be more sensitive to this medication and should be monitored more closely during use. In case of overdose, symptoms such as hypotension, electrolyte imbalance, and dehydration may occur, so contact a healthcare facility immediately for appropriate treatment. Store this medication out of reach of children and keep it in its original container to maintain quality.

Side effects

  • Dizziness
  • fatigue
  • nausea
  • vomiting
  • abnormal urination
  • elevated BUN
  • elevated creatine kinase
  • elevated creatinine
  • orthostatic dizziness
  • headache
Show 79 more
  • syncope
  • hypotension
  • tachycardia
  • edema
  • flushing
  • cough
  • diarrhea
  • dyspepsia
  • altered taste
  • jaundice
  • hepatitis
  • abnormal liver function
  • sexual dysfunction
  • changes in libido
  • kidney function impairment
  • limb edema
  • arthralgia
  • myalgia
  • tinnitus
  • angioedema
  • rash
  • urticaria
  • hyperkalemia
  • decreased serum potassium
  • decreased serum sodium
  • hypotension
  • shingles
  • colon cancer
  • hematoma
  • anaphylactic shock
  • anaphylactic reaction
  • intestinal vascular edema
  • anemia
  • thrombocytopenia
  • hypoglycemia
  • depression
  • sleep disorders
  • orthostatic hypotension
  • arrhythmia
  • aplastic anemia
  • bone marrow suppression
  • neutropenia
  • agranulocytosis
  • hemolytic anemia
  • leukopenia
  • thrombocytopenia
  • dyspnea
  • pancreatitis
  • loss of appetite
  • constipation
  • gastric irritation
  • sialadenitis
  • anorexia
  • interstitial nephritis
  • kidney function impairment
  • jaundice
  • transient blurred vision
  • xanthopsia
  • weakness
  • muscle cramps
  • anaphylaxis-like reaction
  • toxic epidermal necrolysis
  • necrotizing vasculitis
  • erythematous lupus-like reaction
  • erythematous lupus reactivation
  • photosensitivity reaction
  • rash
  • urticaria
  • fever
  • electrolyte imbalance
  • hyperuricemia
  • diabetes
  • hyperglycemia
  • elevated cholesterol
  • elevated triglycerides
  • hypokalemia
  • hyponatremia
  • muscle cramps
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, and the storage temperature should be kept between 1°C and 30°C. Proper storage can help maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Pink, biconvex, oval film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.